Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Spira 80-marker panel for lung cancer

Spira 80-marker panel for lung cancer



QA State: Curated
Short Name:
HGNC Name:

This 80-gene biomarker panel is used to distinguish smokers with lung cancer from smokers without lung cancer. The biomarker panel had approximately 90% sensitivity for stage 1 cancer across all subjects. Adding cytopathology data gives 95% sensitivity and 95% negative predictive value. (7 of the 80 biomarker probesets had no annotated gene symbol associated with them.) List of genes in the panel: DMD, NELL2, FGF14, TMEM47, ANXA3, PLA2G4A, DNAJC12, SLC39A8, DEFB1, PPBP, C6, FCGR3A, IL8, SERPINA1, CXCL2, RGS1, DUSP6, TOB1, FOS, SOX9, CD55, CD55, SLC4A4, CD164, ATP6AP2, ARL6IP5, CCT2, UBXD2, RAB1A, TRAM1, TMED2, YWHAE, C1orf80, TPD52, ACTR2, CPNE3, PTK9, UBE2J1, FXR1, SPN, PPP2CA, AD7C-NTP, STARD7, KIAA0738, RPL35A, GTF2H3, ZNF611, LOC152719, PRR11, ZC3H7B, ZNF354A, UBE2D2, ZNF160, FBXW12, ALMS1, ATP8B1, BACH2, TSR1, HDGF2, FLJ14346, LOC653471, DCLRE1C, DUOX1, LOC153561, DKFZP434A0131, GLT28D1, SENP6, FTO, LMO4, CCDC81, COX5B, FTL, NUCKS1

Panel Details

No member markers defined for this panel.


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Curated


Gene expression in histologically normal large-airway epithelial cells in smokers with the suspicion of lung cancer was studied to determine if a lung cancer biomarker could be developed. Samples were obtained at bronchoscopy and divided into a training set and a testing set. Results showed that gene expression in cytologically normal large-airway epithelial cells can serve as a lung cancer biomarker. This panel biomarker is currently being verified for its application for nasal epithelium.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.